🤖 AI Summary
Overview
This episode explores the cutting-edge science of cellular rejuvenation, a field aiming to reverse aging at the cellular level. It delves into the breakthroughs, challenges, and ethical questions surrounding this research, as well as the billionaires funding it and its potential societal implications.
Notable Quotes
- Why is a baby born young? It seems intuitive, but it’s actually not.
— Susan Dominus, on the biological process of shedding aging markers in embryos.
- The first person who will live to be 150 has already been born.
— Juan Carlos Ipsizua Belmonte, on the potential of longevity science.
- We know how to reverse aging: diet, exercise, and sleep. So why again do we need to invest billions in this?
— Susan Dominus, questioning the necessity of longevity science.
🧬 The Science of Cellular Rejuvenation
- Cellular rejuvenation involves reverting aged cells to a younger state, inspired by the natural process in embryos that sheds aging markers.
- Shinya Yamanaka’s discovery of Yamanaka factors
in 2006 allowed aged mouse cells to revert to embryonic form, earning him a Nobel Prize. However, this process caused dangerous tumors in mice.
- Juan Carlos Ipsizua Belmonte refined the method in 2016, applying Yamanaka factors in moderation to extend the lifespan of prematurely aging mice without causing tumors.
- David Sinclair, a Harvard geneticist, further advanced the field by using a modified version of Yamanaka factors to restore vision in blind mice, with promising results in early monkey trials.
💰 Billionaire Backing of Longevity Science
- Wealthy investors like Sam Altman, Peter Thiel, and Jeff Bezos are pouring billions into longevity startups, including Altos Labs and Retro Biosciences.
- Brian Johnson, a tech VC, has made longevity a spectacle, experimenting with plasma transfusions from his son.
- Altos Labs, backed by Bezos, has recruited top scientists with million-dollar salaries and is exploring alternatives to Yamanaka factors.
🏥 Practical Applications and Ethical Questions
- Early applications of cellular rejuvenation focus on treating diseases like glaucoma and extending organ viability for transplants.
- While some scientists dream of extending human lifespan to 150 years, others aim for modest gains, such as adding 2–3 healthy years to life.
- Ethical concerns include societal impacts, such as strain on social security systems, workforce dynamics, and equitable access to treatments.
🌍 Societal Implications of Living Longer
- Proponents argue that healthier, longer lives could offset population declines and sustain economic productivity.
- Critics worry about potential inequalities and the philosophical implications of dramatically extended lifespans.
- The episode highlights the tension between natural health practices (diet, exercise, sleep) and the allure of technological hacks
to extend life.
🔬 The Role of Technology in Accelerating Research
- Altos Labs is leveraging advanced technologies like AI and organoids (mini human organs grown from stem cells) to improve research efficiency and predict human outcomes more accurately.
- These innovations aim to overcome the limitations of animal models, which often fail to translate to human applications.
AI-generated content may not be accurate or complete and should not be relied upon as a sole source of truth.
📋 Episode Description
The quest for a “cure” for aging — a way to remain youthful, even as we get older — is a project as old as humanity. It’s also a big business; products, therapies and treatments intended to moderate or reverse aging are part of a $2 trillion global wellness market that’s only getting bigger.
But there have been some recent breakthroughs in the science of longevity that could be pivotal for the field. These discoveries have to do with cellular rejuvenation, which is the idea that scientists could take a cell that has aged, and make it function like a younger version of itself.
On this episode of “The Sunday Daily,” the host Rachel Abrams talks with Susan Dominus, a staff writer at The New York Times Magazine, about this new research, the scientists behind it and who is funding this scientific quest for longer lives.
On Today’s Episode:
Susan Dominus is a staff writer at The New York Times Magazine.
Background Reading:
Longevity Science Is Overhyped. But This Research Really Could Change Humanity.
Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.